NSE/GLAND

GLANDGland Pharma Ltd

Healthcare · NSE

₹1,797.4+3.56%

52-wk low52-WEEK RANGE52-wk high

₹1,392.8+29.0% from low ·-14.5% from high₹2,102.1

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

GLAND+29.05% · 1Y

Range high ₹2,131Range low ₹1,342Latest ₹1,797.4252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareDrug Manufacturers - Specialty & GenericMidcapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite25/100

Performance

Low

Hasn't fared well — amongst the weak performers.

· 52w return +22.7%
· Below 200-DMA (-2.6%) — downtrend

Valuation

Low

Appears to be fairly valued to cheap vs peers.

· P/E 34.7 close to sector median 37.8
· P/B 3.07 below sector median 5.81

Growth

Low

Lagging the market in growth.

· Revenue YoY -0.8% — contracting
· Profit YoY -9.6% — earnings slipping

Profitability

Low

Profitability is a concern.

· ROE 8.9% — weak returns on equity

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(71/100)

Durability

79/100

Financially resilient — strong quality + solvency profile.

Show 4 drivers

Piotroski F-score6/9 (67pt)
Altman Z" score8.20 (100pt)
Debt/Equity0.03 (100pt)
ROE8.9% (35pt)

Valuation

67/100

Fairly priced — not a bargain, not stretched.

Show 4 drivers

P/E vs sector (34.7 / 37.8)92% (71pt)
P/B3.07 (100pt)
Dividend yield1.00% (25pt)
EV/EBITDA18.8 (40pt)

Momentum

66/100

Constructive setup — momentum building, not extended.

Show 5 drivers

52w change+22.7% (73pt)
DMA-trend alignmentsideways (50pt)
RSI (14)62.2 (93pt)
Price vs 200-DMA-1.9% (50pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)34.71

FAIR

CheapestP/E 34.7 near sector median.Most expensive

P/B3.07

UNDERVALUED

CheapestP/B 3.07 at 25th %ile of sector.Most expensive

EV/EBITDA18.82

OVERVALUED

Monthly seasonality

Avg monthly return over 6 years · historical — not a forecast

Best: Jul +10.30% · Worst: Jan -7.29%

Jan

-7.3%

33% win

Feb

+0.1%

50% win

Mar

-0.0%

67% win

Apr

+0.6%

50% win

May

-1.7%

60% win

Jun

+6.5%

Monthly return distribution

Distribution of 65 monthly returns

Mean

+0.36%

Median

-0.53%

Std dev

11.04%

Best

+33.2%

Worst

-32.0%

% positive

48%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 2

Lean balance sheet (D/E 0.03)
Low leverage means earnings are less sensitive to rate cycles
Bankruptcy risk low (Altman Z″ 8.20)
Z″ above 2.60 sits squarely in the 'safe' zone

WEAKNESSES · 2

Low return on equity (8.9%)
Below 10% ROE suggests inefficient use of shareholder capital
Revenue contracting (-0.8% YoY)
Negative top-line growth is the hardest signal to overcome

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 0

No immediate threats from the data

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+3.6%

+3.2%

+10.5%

+6.1%

-9.3%

+26.1%

+13.3%

-6.3%

10Y

-0.2%

Fundamentals

VALUATION

Market cap

₹29,399 Cr

P/E (TTM)

34.7

P/E (fwd)

24.9

next 12m

P/B

3.07

EV/EBITDA

18.8

Book value

₹580.47

per share

PROFITABILITY · QUALITY

ROE

8.9%

ROCE

—

Net margin

12.4%

Op margin

19.3%

Gross margin

58.9%

D/E

0.03

GROWTH · MARKET

Rev YoY

-0.8%

Profit YoY

-9.6%

Div yield

1.00%

Payout

35.0%

52w change

+22.7%

Beta

0.41

defensive

Pros and cons

Auto-derived from ratios · not a buy/sell recommendation

PROS · 2

+Forward P/E materially below trailing (24.9x vs 34.7x)Street expects earnings growth that compresses the multiple — positive surprise cushion
+Nearly debt-free (D/E 0.03)Low financial risk — funds growth from internal accruals, resilient in downturns

CONS · 2

−Low ROE of 8.9%Below the 10%+ threshold most quality-focused investors require
−Revenue declining -0.8% YoYTop-line contraction — watch for cyclical vs structural

Sector-relative context

Healthcare · 24 peers

P/E (TTM)

This stock

34.71

Sector median

37.85

Rank 12/24 (54th %ile)

ROE

This stock

8.9%

Sector median

13.8%

Rank 11/24 (58th %ile)

P/B

This stock

3.07

Sector median

5.81

Rank 6/24 (79th %ile)

Quality score · Piotroski F-score

6 / 9

Decent quality — clears Piotroski bar

✓Profitable (positive net income)· Most basic check — company makes money
✓Positive return on assets· Assets generate returns
✓Positive operating cash flow· Profits are backed by real cash, not accruals
✗Operating CF exceeds net profit· Healthy cash conversion — no aggressive revenue recognition
✗Long-term debt decreased YoY· Deleveraging — lower refinancing risk
✓ROA improved YoY· Getting more productive with the asset base
✓Operating margin expanded YoY· Pricing power or cost discipline
✓

Forensic score · Altman Z″ (emerging markets)

Bankruptcy-risk predictor · 1995 Altman emerging-market revision

SAFE8.20

Z″ = 8.20 — well inside the SAFE zone. Low bankruptcy risk signal across liquidity, profitability and solvency inputs.

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.409	×6.56	2.681
Retained Earnings / Total Assets (B)	0.668	×3.26	2.178
EBIT / Total Assets (C)	0.179	×6.72	1.201
Book Equity / Total Liabilities (D)	2.033	×1.05	2.135

Zones: Z″ ≥ 2.60 safe · 1.10–2.60 grey · < 1.10 distress. All four inputs derived from latest annual filing.

Analyst consensus

13 analysts · HOLD

Target mean

₹1962.77

Target high

₹2500.00

Target low

₹1525.00

Upside vs today

+10.0%

Street consensus target is +10.0% vs current price. Consensus is a lagging sentiment read, not a forecast.

Company + balance sheet snapshot

Industry

Drug Manufacturers - Specialty & Generic

Employees

4,351

Shares out

16.5

Revenue (TTM)

₹6,113 Cr

EBITDA

₹1,419 Cr

Total debt

₹302 Cr

Cash

₹3,202 Cr

Net debt

₹-2,900 Cr

Quarterly results

Last 5 quarters · ₹ Cr (Screener.in-grade depth)

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q4
Revenue	1,406	1,384	1,392	1,506	1,695
Operating profit	203	264	251	267	327
OPM %	14.5%	19.1%	18.0%	17.7%	19.3%
Interest	6	23

Annual P&L

Last 4 years · ₹ Cr · all line items

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	4,384	3,592	5,642	5,584
Operating profit	1,400	870	996	890
OPM %	31.9%	24.2%	17.7%	15.9%
Interest	3	6	22	37
Depreciation

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
GLANDTHIS Gland Pharma Limited	₹1,797.4	+22.7%	29,399	34.7	3.07	8.9%	0.03	-0.8%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%

ASK AXEL

Dig deeper into GLAND

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for GLAND — all in one sourced reply.

Ask free in chat

Run these tools on GLAND

Historical return →

"If I had bought GLAND in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on GLAND

Brokerage + charges →

All-in cost for trading GLAND

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	14.39	16.98	+18.0%
-2q	12.96	11.15	-14.0%
-3q	13.28	13.33	+0.4%
-4q	14.13	11.32	-19.9%

Date	Amount
2025-08-14	₹18.00
2024-08-16	₹20.00

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	16	16	16	16
Reserves	5,234	6,015	6,788	7,157
Borrowings	5	4	372	314
Other liabilities	—	—	40	41
Total liabilities	7,834	8,778	10,661	11,225
Fixed assets	1,727	1,799	3,871	3,975
CWIP	227	240	279	182
Investments	200	—	655	—
Other assets	84	106	98	65
Total assets	7,834	8,778	10,661	11,225

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	791	364	997	915
CF Investing	-1,003	1,208	-1,757	1,705
CF Financing	35	15	-799	-433
Net cash flow	-174	1,590	-1,552	2,199
Free cash flow	269	141	599	521

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	15.9%	17.7%	24.2%	31.9%
Net margin %	12.5%	13.7%	21.7%	27.6%
ROE %	10.0%	12.0%	13.8%	23.1%
ROCE %	15.0%	17.5%	18.8%	30.9%
Debt / Equity	0.04	0.05	0.00	0.00
Interest coverage	29.4×	53.0×	168.7×	477.0×
Revenue growth YoY	-1.0%	+57.1%	-18.1%	—
Profit growth YoY	-9.6%	-1.1%	-35.5%	—

GLANDGland Pharma Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Peer comparison · Healthcare

Ask Axel about GLAND

Recent news

Dig deeper into GLAND

Run these tools on GLAND

Technical snapshot

Earnings history + surprises

Dividends + splits history

Recent news

Stock scorecard

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare